These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 783228)

  • 1. Management of a lacerated frenum and lip in a child with severe hemophilia and an inhibitor: report of case.
    Powell D
    ASDC J Dent Child; 1976; 43(4):272-5. PubMed ID: 783228
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dental treatment of a hemophilic patient].
    Olivier M
    J Dent Que; 1981 Feb; 18():55-8. PubMed ID: 6785330
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating antibodies in factor VIII deficiency hemophilia: report of case.
    Cudzinowski L
    ASDC J Dent Child; 1979; 46(1):54-6. PubMed ID: 283081
    [No Abstract]   [Full Text] [Related]  

  • 4. Circulating antibodies in factor VIII deficiency hemophilia: report of case.
    Hanna JD
    ASDC J Dent Child; 1979; 46(3):259. PubMed ID: 285955
    [No Abstract]   [Full Text] [Related]  

  • 5. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST; Addiego JE; Reason DC; Lucas AH
    Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-factor VIII antibodies in children with hemophilia, and the management of hemorrhage].
    Klukowska A; Adamowicz-Salach A; Kamińska D; Zieleniewska B
    Pol Tyg Lek; 1987 Jul; 42(30):911-4. PubMed ID: 3118341
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemophilia in childhood.
    McNeill GF; Schwartz E
    Pa Med; 1975 Jan; 78(1):51-3. PubMed ID: 1128902
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitor development in a multitransfused patient with severe haemophilia A.
    van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP
    Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
    [No Abstract]   [Full Text] [Related]  

  • 9. [Incidence of the appearance of factor VIII inhibitor in patients with hemophilia A at the Hemophilia Center of the Clinical Hospital Center in Zagreb].
    Ficović P; Tiefenbach A; Brkljacić V; Grgić Z
    Lijec Vjesn; 1983 Oct; 105(10):410-1. PubMed ID: 6418997
    [No Abstract]   [Full Text] [Related]  

  • 10. [Occurrence of anti-factor VIII antibodies in children with hemophilia].
    Klukowska A; Adamowicz-Salach A; Kamińska D
    Acta Haematol Pol; 1987; 18(1-2):123-6. PubMed ID: 3124483
    [No Abstract]   [Full Text] [Related]  

  • 11. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT; Lee CA
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract]   [Full Text] [Related]  

  • 12. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Importance of corticoids in inhibitor suppression in hemophilia A, in addition to continuing treatment with factor VIII concentrate].
    Aznar JA; Jorquera JI; Marty ML
    Sangre (Barc); 1983; 28(3):265-79. PubMed ID: 6414098
    [No Abstract]   [Full Text] [Related]  

  • 15. Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies.
    Leggett PL; Doyle D; Smith WB; Culpepper W; Cooper S; Ochsner JL
    J Thorac Cardiovasc Surg; 1984 Apr; 87(4):556-60. PubMed ID: 6423912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 18. Reactivation of chronic hepatitis C virus infection by immunoadsorption in factor VIII inhibitor haemophilia.
    Rommel F; Toepfer M; Eberle J; Schiffl H; Spannagl M; Schramm W
    Thromb Haemost; 2000 Oct; 84(4):733-4. PubMed ID: 11057884
    [No Abstract]   [Full Text] [Related]  

  • 19. Physiologic considerations in the management of hemophilia.
    Briggs DK
    Pathobiol Annu; 1971; 1():205-14. PubMed ID: 4950380
    [No Abstract]   [Full Text] [Related]  

  • 20. [Combined plasmapheresis and immunosuppression in hemophilia in a patient with antibodies].
    Révész T; Mátyus J; Goldschmidt B; Harsányi V
    Orv Hetil; 1980 Jul; 121(29):1753-4. PubMed ID: 6779250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.